These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 7890056)
1. Ovarian influence on adrenal androgen secretion in polycystic ovary syndrome. Fruzzetti F; De Lorenzo D; Ricci C; Teti G Fertil Steril; 1995 Apr; 63(4):734-41. PubMed ID: 7890056 [TBL] [Abstract][Full Text] [Related]
2. Hyperandrogenism in women with polycystic ovary syndrome persists after menopause. Markopoulos MC; Rizos D; Valsamakis G; Deligeoroglou E; Grigoriou O; Chrousos GP; Creatsas G; Mastorakos G J Clin Endocrinol Metab; 2011 Mar; 96(3):623-31. PubMed ID: 21177795 [TBL] [Abstract][Full Text] [Related]
3. Evidence for heterogeneous etiologies of adrenal dysfunction in polycystic ovary syndrome. Gonzalez F; Chang L; Horab T; Lobo RA Fertil Steril; 1996 Sep; 66(3):354-61. PubMed ID: 8751729 [TBL] [Abstract][Full Text] [Related]
4. Gonadotrophin and gonadal steroid response to a single dose of a long-acting agonist of gonadotrophin-releasing hormone in ovulatory and anovulatory women with polycystic ovary syndrome. White D; Leigh A; Wilson C; Donaldson A; Franks S Clin Endocrinol (Oxf); 1995 May; 42(5):475-81. PubMed ID: 7621565 [TBL] [Abstract][Full Text] [Related]
8. Adrenal dynamic responses to physiologic and pharmacologic adrenocorticotropic hormone stimulation before and after ovarian steroid modulation in women with polycystic ovary syndrome. Gonzalez F; Chang L; Horab T; Stanczyk FZ; Crickard K; Lobo RA Fertil Steril; 1999 Mar; 71(3):439-44. PubMed ID: 10065779 [TBL] [Abstract][Full Text] [Related]
9. Ovarian 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone (GnRH) agonist challenge in women with polycystic ovary syndrome is not mediated by luteinizing hormone hypersecretion: evidence from GnRH agonist and human chorionic gonadotropin stimulation testing. Ibañez L; Hall JE; Potau N; Carrascosa A; Prat N; Taylor AE J Clin Endocrinol Metab; 1996 Nov; 81(11):4103-7. PubMed ID: 8923867 [TBL] [Abstract][Full Text] [Related]
10. Determination of the source of androgen excess in functionally atypical polycystic ovary syndrome by a short dexamethasone androgen-suppression test and a low-dose ACTH test. Rosenfield RL; Mortensen M; Wroblewski K; Littlejohn E; Ehrmann DA Hum Reprod; 2011 Nov; 26(11):3138-46. PubMed ID: 21908468 [TBL] [Abstract][Full Text] [Related]
11. How common are polycystic ovaries and the polycystic ovarian syndrome in women with Cushing's syndrome? Kaltsas GA; Korbonits M; Isidori AM; Webb JA; Trainer PJ; Monson JP; Besser GM; Grossman AB Clin Endocrinol (Oxf); 2000 Oct; 53(4):493-500. PubMed ID: 11012575 [TBL] [Abstract][Full Text] [Related]
12. Adrenal hyperandrogenism is induced by fetal androgen excess in a rhesus monkey model of polycystic ovary syndrome. Zhou R; Bird IM; Dumesic DA; Abbott DH J Clin Endocrinol Metab; 2005 Dec; 90(12):6630-7. PubMed ID: 16174719 [TBL] [Abstract][Full Text] [Related]
13. A comparison between the effects of low dose (1 microg) and standard dose (250 microg) ACTH stimulation tests on adrenal P450c17alpha enzyme activity in women with polycystic ovary syndrome. Colak R; Keleştimur F; Unlühizarci K; Bayram F; Sahin Y; Tutuş A Eur J Endocrinol; 2002 Oct; 147(4):473-7. PubMed ID: 12370108 [TBL] [Abstract][Full Text] [Related]
14. Long-term administration of gonadotropin-releasing hormone agonist and dexamethasone: assessment of the adrenal role in ovarian dysfunction. Cedars MI; Steingold KA; de Ziegler D; Lapolt PS; Chang RJ; Judd HL Fertil Steril; 1992 Mar; 57(3):495-500. PubMed ID: 1531463 [TBL] [Abstract][Full Text] [Related]
15. Ovarian suppression with triptorelin and adrenal stimulation with adrenocorticotropin in functional hyperadrogenism: role of adrenal and ovarian cytochrome P450c17 alpha. Escobar-Morreale H; Pazos F; Potau N; García-Robles R; Sancho JM; Varela C Fertil Steril; 1994 Sep; 62(3):521-30. PubMed ID: 8062947 [TBL] [Abstract][Full Text] [Related]
16. Adrenal and ovarian steroid hormone responses to gonadotropin-releasing hormone agonist treatment in polycystic ovary syndrome. Gonzalez F; Hatala DA; Speroff L Am J Obstet Gynecol; 1991 Sep; 165(3):535-45. PubMed ID: 1832519 [TBL] [Abstract][Full Text] [Related]
17. Adrenal androgen excess in the polycystic ovary syndrome: sensitivity and responsivity of the hypothalamic-pituitary-adrenal axis. Azziz R; Black V; Hines GA; Fox LM; Boots LR J Clin Endocrinol Metab; 1998 Jul; 83(7):2317-23. PubMed ID: 9661602 [TBL] [Abstract][Full Text] [Related]
18. Ovulation after glucocorticoid suppression of adrenal androgens in the polycystic ovary syndrome is not predicted by the basal dehydroepiandrosterone sulfate level. Azziz R; Black VY; Knochenhauer ES; Hines GA; Boots LR J Clin Endocrinol Metab; 1999 Mar; 84(3):946-50. PubMed ID: 10084576 [TBL] [Abstract][Full Text] [Related]
19. Androgen responses to adrenocorticotropic hormone infusion among individual women with polycystic ovary syndrome. Maas KH; Chuan S; Harrison E; Cook-Andersen H; Duleba AJ; Chang RJ Fertil Steril; 2016 Oct; 106(5):1252-1257. PubMed ID: 27473350 [TBL] [Abstract][Full Text] [Related]
20. Assessment of the adrenal-ovarian contribution by short-term dexamethasone and ACTH tests in hyperandrogenized patients. Fulghesu AM; Lanzone A; Apa R; Fortini A; Caruso A; Mancuso S Gynecol Endocrinol; 1991 Mar; 5(1):37-48. PubMed ID: 1654730 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]